TORL BioTherapeutics Enhances Leadership with Key Executive Appointments in Oncology

Enhancing Leadership for Innovative Oncology Therapy Development

TORL BioTherapeutics LLC, known for its cutting-edge work in oncology, has announced a significant shift in its leadership team that aims to drive its strategic vision forward. In a recent press release dated October 16, 2026, the company shared that it has appointed Sandip Kapadia as Chief Financial Officer and Eric Sievers, M.D., as Chief Medical Officer. These appointments are pivotal components of TORL’s year-long plan to bolster its management in line with its promising portfolio of antibody-based therapeutics.

Sandip Kapadia: A Seasoned Financial Leader

Sandip Kapadia joins TORL with over three decades of extensive experience in the life sciences sector. He has a remarkable history of formulating growth strategies and executing capital formation effectively. His former role as Chief Financial and Administrative Officer at Harmony Biosciences saw the company transition into a profitable phase, creating considerable impact. Kapadia’s expertise has been instrumental in raising over $2 billion in public capital for various emerging biotechnology entities, showcasing his prowess in navigating complex financial landscapes.

Eric Sievers: A Clinical Trailblazer

Simultaneously, Dr. Eric Sievers, who also brings over 30 years of substantial expertise in oncology, has been appointed as Chief Medical Officer. His focus has revolved around leading clinical and translational research primarily targeting antibody-drug conjugates (ADCs) for both solid and hematologic malignancies. Dr. Sievers previously held the title of Chief Medical Officer at BioAtla, where he was instrumental in overseeing critical first-in-human studies and pivotal trials, especially regarding ADCETRIS and MYLOTARG – both of which have achieved FDA approval during his tenure.

Strategic Moves to Propel Forward

With these key appointments, TORL is poised to enhance its therapeutic offerings, particularly its leading asset, ixotatug vedotin (Ixo-V). Ixo-V stands out for being the first ADC that selectively targets Claudin 6, and it is currently under evaluation for various malignancies. The combined leadership of Kapadia and Sievers not only reflects TORL’s commitment to advancing its innovative approaches to cancer treatment but also signals a significant phase of growth and organizational scale ahead.

Aran Maree, M.D., the Chief Executive Officer of TORL, expressed enthusiasm for the new strategic alignments: "We are thrilled to bring Sandip and Eric onto our leadership team at such a vital stage of our development. Their extensive backgrounds in life sciences will be critical as we move forward with Ixo-V and our entire pipeline. Together, we will be addressing the substantial opportunities that lie ahead in the oncology landscape."

Farewell to Former Chairman

In related news, TORL also announced the retirement of Mark Alles from his role as Chairman of the Board. His leadership has been pivotal in guiding TORL through a transformative period since 2022. He plans to remain with the company as a strategic advisor, ensuring a seamless transition while leveraging his expertise to guide future initiatives.

A Future Bright with Potential

TORL BioTherapeutics is on an exciting trajectory with its unique focus on developing innovative antibody-based therapeutics against groundbreaking targets in oncology. With financial and medical leaders such as Kapadia and Sievers now at the forefront, stakeholders can anticipate vigorous growth, leading the way in therapeutic advancements to improve patient outcomes in the fight against cancer. The company's mission aligns well with addressing the pressing healthcare needs, positioning them as a key player in the biotechnology sector moving forward.